Speakers:
 |
|
 |
Andrew Carpenter
EVP, Manufacturing, Science & Technology,
Phlow Corporation |
|
William DuBay
Global Head of R&D,
SK pharmteco |
About our Speakers:
Andrew Carpenter is a 20+ year veteran of the pharmaceutical industry, where he started his career in drug discovery with the goal of identifying life-saving medicines or medicines that impacted the quality of life for patients. During his career at Searle and GSK, Andrew has led projects in multiple therapeutic areas (cardiovascular, obesity, diabetes) as well as different modalities (small molecule, peptide). Andrew then carried his project leadership experience to the contract manufacturing industry, where he expanded his skill set into API (AMPAC Fine Chemicals) and drug product (Alcami) manufacturing and found a new passion in continuous manufacturing. In 2020, Andrew joined Phlow™ to help build their world-class development capabilities in addition to using strategic partnerships to reliably supply affordable, high-quality essential medicines through US-based advanced manufacturing.
About Phlow Corporation
Phlow Corp. is a trailblazing, essential medicines impact company that is reimagining essential medicines from start to finish using flow chemistry and other advanced development and manufacturing processes. Everything Phlow does is designed to promote access to affordable, high-quality essential medicines for all Americans. Phlow provides a solution to the broken essential medicines supply chain by offering a resilient end-to-end solution that is U.S.-based, comprehensive, and fully integrated. With the support of an industry leading team, experienced strategic partners, and established relationships at the policy, regulatory, and federal levels, Phlow will develop and manufacture active pharmaceutical ingredients (APIs) and finished pharmaceutical products domestically for essential medicines critical to the nation’s healthcare. Using continuous-flow processes and other green chemistry approaches, Phlow is able to reduce costs and waste, improve quality and yield, and offer a more environmentally friendly alternative to batch manufacturing.
Learn more about Phlow’s growing efforts to use continuous-flow and other advanced manufacturing technologies to reduce costs, improve quality, and sustain our environment at www.phlow-usa.com.
Bill DuBay has more than 25 years of experience in Pharmaceutical Research and Development. Bill is currently the global head of R&D for SK pharmteco, and prior to that he was Vice President R&D for AMPAC Fine Chemicals where he was responsible for developing the product pipeline, API manufacturing and API validation. He has also held roles in Project Management and R&D Management at both DSM and AMPAC Fine Chemicals. Dr. DuBay received his PhD in organic chemistry from the University of South Carolina and conducted post-doctoral studies at Indiana University.
ABOUT SK PHARMTECO
SK pharmteco is a U.S.-based Contract Manufacturing Organization (CMO) that consolidates the operations of AMPAC Fine Chemicals and SK biotek Korea and Ireland. The company has global manufacturing facilities with demonstrated capabilities in process development, scale-up, and cGMP-compliant commercial production of active pharmaceutical ingredients and registered intermediates for pharmaceutical and biotechnology customers worldwide. SK pharmteco Headquarters are in Sacramento, California with AMPAC Fine Chemicals operations in Rancho Cordova and El Dorado Hills, California, La Porte, Texas, and Petersburg, Virginia, U.S. and SK biotek operations in Swords, Ireland, and Daejeon and Sejong, Korea. For more information, you can visit us at ampacfinechemicals.com and SKbiotek.com.